Syndax Pharmaceuticals Inc (SNDX) — SEC Filings
Syndax Pharmaceuticals Inc (SNDX) — 32 SEC filings. Latest: 8-K (Dec 19, 2025). Includes 11 8-K, 10 SC 13G/A, 5 10-Q.
View Syndax Pharmaceuticals Inc on SEC EDGAR
Overview
Syndax Pharmaceuticals Inc (SNDX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 3, 2025: Syndax Pharmaceuticals Inc. reported a significant increase in total revenues to $103.624 million for the nine months ended September 30, 2025, up from $16.000 million in the same period of 2024. This surge was primarily driven by product revenue, net, of $80.649 million and collaboration revenue, n
Sentiment Summary
Across 32 filings, the sentiment breakdown is: 1 bearish, 30 neutral, 1 mixed. The dominant filing sentiment for Syndax Pharmaceuticals Inc is neutral.
Filing Type Overview
Syndax Pharmaceuticals Inc (SNDX) has filed 11 8-K, 5 10-Q, 2 DEF 14A, 2 10-K, 10 SC 13G/A, 2 SC 13G with the SEC between Jan 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (32)
Risk Profile
Risk Assessment: Of SNDX's 20 recent filings, 2 were flagged as high-risk, 10 as medium-risk, and 8 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $103.624M |
| Net Income | -$217.408M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $116.808M |
| Operating Margin | N/A |
| Total Assets | $551.792M |
| Total Debt | N/A |
Key Executives
- Dr. Michael S. Brown
- Michael A. Metzger
- Briggs W. Morrison
- Michael M. Morrissey
Industry Context
Syndax Pharmaceuticals operates in the highly competitive biopharmaceutical industry, focusing on innovative cancer therapies. The sector is characterized by significant R&D investment, long development cycles, and stringent regulatory oversight. Success hinges on clinical trial outcomes, regulatory approvals, and effective commercialization of novel treatments.
Top Tags
Biotechnology (4) · pharmaceuticals (4) · 10-Q (3) · financials (3) · leadership-change (3) · Syndax Pharmaceuticals (3) · institutional-ownership (3) · amendment (3) · Pharmaceuticals (2) · Oncology (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Total Revenues | $103.624M | Increased from $16.000M in 2024 for the nine months ended September 30, 2025, driven by new product sales. |
| Product Revenue, net | $80.649M | Generated for the nine months ended September 30, 2025, compared to $0 in 2024, indicating successful commercialization. |
| Net Loss | $217.408M | For the nine months ended September 30, 2025, a slight improvement from $224.589M in 2024, but still substantial. |
| Net Cash Used in Operating Activities | $253.492M | For the nine months ended September 30, 2025, indicating significant cash burn. |
| Cash and Cash Equivalents | $116.808M | As of September 30, 2025, down from $154.083M at December 31, 2024. |
| Research and Development Expenses | $180.143M | For the nine months ended September 30, 2025, a key driver of operating expenses. |
| Selling, General and Administrative Expenses | $129.753M | For the nine months ended September 30, 2025, up from $83.189M in 2024, reflecting commercialization efforts. |
| Shares Outstanding | 86,914,838 | As of October 31, 2025, indicating potential dilution from equity compensation. |
| Net Loss (Q2 2025) | $60.2M | Increased from $55.1M in Q2 2024, indicating widening losses. |
| Net Loss (YTD June 2025) | $118.9M | Increased from $108.5M in YTD June 2024, showing a sustained increase in losses. |
| R&D Expenses (Q2 2025) | $49.5M | Slight decrease from $50.3M in Q2 2024, but still a major expense. |
| SG&A Expenses (Q2 2025) | $12.8M | Increased from $10.1M in Q2 2024, contributing to higher operating costs. |
| Collaboration Revenue (Q2 2025) | $1.0M | Decreased from $1.2M in Q2 2024, indicating reduced external funding. |
| Cash and Cash Equivalents (June 30, 2025) | $350.5M | Provides liquidity for ongoing operations and clinical trials. |
| Increase in Q2 Net Loss | 9.3% | Percentage increase in net loss from Q2 2024 to Q2 2025. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Syndax Pharmaceuticals Inc (SNDX)?
Syndax Pharmaceuticals Inc has 32 recent SEC filings from Jan 2024 to Dec 2025, including 11 8-K, 10 SC 13G/A, 5 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of SNDX filings?
Across 32 filings, the sentiment breakdown is: 1 bearish, 30 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Syndax Pharmaceuticals Inc SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Syndax Pharmaceuticals Inc (SNDX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Syndax Pharmaceuticals Inc?
Key financial highlights from Syndax Pharmaceuticals Inc's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for SNDX?
The investment thesis for SNDX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Syndax Pharmaceuticals Inc?
Key executives identified across Syndax Pharmaceuticals Inc's filings include Dr. Michael S. Brown, Michael A. Metzger, Briggs W. Morrison, Michael M. Morrissey.
What are the main risk factors for Syndax Pharmaceuticals Inc stock?
Of SNDX's 20 assessed filings, 2 were flagged high-risk, 10 medium-risk, and 8 low-risk.
What are recent predictions and forward guidance from Syndax Pharmaceuticals Inc?
Forward guidance and predictions for Syndax Pharmaceuticals Inc are extracted from SEC filings as they are enriched.